Auswirkungen der Dosiseskalation im Rahmen der Brachytherapie auf posttherapeutische Lebensqualität, Miktionskontrolle und PSA-Verlauf
Auch gedruckt in der BibliothekZ: J-H 11.952; W: W-H 11.437
Ressourcen- / MedientypDissertation, Text
Datum der Freischaltung2008-06-18
Purpose: To investigate changes in quality of life (QoL), urinary incontinence and biochemical control rates after permanent prostate brachytherapy with dose-escalation (D90>160Gy). Materials and Methods: 182 patients, treated with brachytherapy between 2000 and 2005, received two validated questionnaires (European Organization for Research and Treatment of Cancer QLQ-C30 instrument [EORTC QLQ-C30]; International Prostate Symptom Score [IPSS]) at least 4 months after brachytherapy. Patients were separated into two groups: control group (D90<160Gy) and test group with dose-escalation (D90>160Gy). Differences concerning QoL were verified by unpaired t-test and Mann-Whitney u-test. The Kaplan-Meier method was used to construct survival curves regarding biochemical outcome. Results: The assessment of the QoL between control and test group revealed no relevant differences in the functional scale scores 4 months after brachytherapy or later, and the same was true of the symptom scales. 28 % of the patients with dose-escalation experienced erectile dysfunction; urinary function did not get worse significantly, 84 % of the patients reported on normal continence. Biochemical control rate after 4 years was 98,2%. Conclusions: The results of the present study confirm that brachytherapy with dose-escalation (D90>160Gy) showed comparable functional results to brachytherapy without dose-escalation (D90<160Gy) and predict in additon longer biochemical recurrence-free survival; thus brachytherapie with dose-escalation seems to be a promising possibility to improve local control.
LizenzStandard (Fassung vom 03.05.2003)
Prostatic neoplasms. Therapy